Photo taken from ESMO/LinkedIn
Sep 15, 2024, 09:40
The final analysis of the KEYNOTE-811 trial presented at ESMO24
ESMO shared on LinkedIn:
“As presented at ESMO24, the final analysis of the KEYNOTE-811 trial reports statistically significant improvement in OS with first-line pembrolizumab versus placebo added to trastuzumab and chemotherapy in patients with unresectable, HER2-positive metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, regardless of PD-L1 status.
For Filippo Pietrantonio, the clinically meaningful data suggest that the immunotherapy combination will now become the standard-of-care comparator arm for future first-line phase III Clinical Trials in this setting.
Read the full article on the ESMO Daily Reporter.”
Source: ESMO/LinkedIn
More posts featuring ESMO24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 23:35
Nov 13, 2024, 23:33
Nov 13, 2024, 23:28
Nov 13, 2024, 23:26
Nov 13, 2024, 23:22
Nov 13, 2024, 23:18
Nov 13, 2024, 19:25